Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A Combination Drug for Immunotherapy of Malignant Tumors

A technology for immunotherapy and malignant tumors, which is applied in the field of medicine, can solve the problems of unclear mechanism of action of traditional Chinese medicine, incomplete target protein, and increased difficulty in obtaining it, so as to improve the immune microenvironment of tumors, promote maturation and differentiation, and improve the body's immunity Effect

Active Publication Date: 2020-12-15
君维安(武汉)生命科技有限公司
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chinese patent CN201480014872.1 discloses the targeted delivery of probiotics and / or therapeutic agents to the gastrointestinal tract, both of which use intestinal probiotics as carriers and traditional Chinese medicine or traditional Chinese medicine ingredients as active substances to achieve the purpose of treating tumors or anticancer However, the mechanism of action of traditional Chinese medicine is not yet clear, and the pertinence is not strong, and the function of intestinal probiotics may be inhibited when combined with traditional Chinese medicine as a carrier
Chinese patent CN00819253.7 discloses the application of drug combination drugs containing interleukin-2 in pharmaceuticals, and Chinese patent CN200410025249.4 discloses the fusion protein of tumor necrosis treatment monoclonal antibody-interleukin 2 and its preparation method and application. Patients are treated with interleukin 2 alone or with carrier protein fusion therapy. There are deficiencies in the use of interleukin 2 alone to act on the tumor immune microenvironment. Although the fusion protein can improve the curative effect, the cost is high and it is easy to appear incomplete. target protein, which increases the difficulty of obtaining and affects the function of the protein itself

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A Combination Drug for Immunotherapy of Malignant Tumors
  • A Combination Drug for Immunotherapy of Malignant Tumors
  • A Combination Drug for Immunotherapy of Malignant Tumors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0033] Embodiment: the pharmacological test of different groups of drugs

[0034] 1. Materials and methods

[0035] 1.1 Preparation of live bacteria freeze-dried powder:

[0036] 1) Bacterial recovery: thaw the strains stored at -80°C, and inoculate them in liquid medium with an inoculation loop.

[0037] 2) Bacterial activation: After the activation of the bacteria is successful, first streak the plate, pick a single colony visible to the naked eye, and carry out expansion culture and culture to the logarithmic phase.

[0038] 3) Bacteria collection: Bacteria cultured in liquid to the logarithmic phase, centrifuged at 8000rpm at room temperature for 5-10min, discarding the supernatant.

[0039]4) Bacterial washing: Wash once with equal volume and half volume of normal saline, centrifuge at 8000rpm for 5-10min at room temperature, and discard the supernatant.

[0040] 5) Resuspension bottling: Resuspend the processed bacteria with an appropriate volume (1:4) of cryoprotecta...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a combined drug for immunotherapy of malignant tumors. The combined drug includes a preparation containing interleukin 2, and a preparation containing intestinal probiotics; the pharmacological studies confirm that the combined drug of the present invention has a function of reducing tumor burden and controlling tumor growth, can promote the infiltration of cytotoxic T cells and the differentiation and differentiation of dendritic cells, improve the tumor immune microenvironment, can make up for the deficiency of the interleukin 2 alone in the tumor immune microenvironment, and can be applied to the immunotherapy of various malignant tumors.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a combined drug for immunotherapy of malignant tumors. Background technique [0002] Malignant tumors have gradually become one of the major threats to human health. At present, traditional treatment methods mainly include surgical resection, radiotherapy, chemotherapy, tumor-targeted drugs, adoptive immunotherapy, and tumor vaccines. Traditional tumor therapy has shown a "ceiling effect". With the deepening of research on tumor immunology, cell biology and molecular technology, tumor immunotherapy has become a research hotspot in the past few years, opening up a new direction for tumor treatment. Tumor immunotherapy is a therapeutic method that enables the body to generate a tumor-specific immune response in an active or passive manner, restores or improves the activity of the body's immune system, and fully exerts its ability to inhibit and kill tumor cells. Tumor immunoth...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/20A61K35/742A61K35/745A61K35/741A61P35/00
CPCA61K35/741A61K35/742A61K35/745A61K38/2013A61P35/00A61K2300/00
Inventor 刘智杨祥良石林林盛剑勇
Owner 君维安(武汉)生命科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products